Agathe Landoas
Hospital pharmacist at Grenoble Alpes University Hospital who studies how everolimus is used after lung transplantation and whether it protects the new lungs from long-term rejection
Pharmacy Department, Grenoble Alpes University Hospital and Universite Grenoble Alpes, France (affiliation on PubMed papers from 2021 to 2026)
Agathe Landoas is the first author of LANDOAS2026, a study of people who had received a lung transplant. The biggest long-term threat to a transplanted lung is chronic lung allograft dysfunction (CLAD), a slow scarring and narrowing of the airways caused largely by the immune system. Everolimus, a drug that blocks mTOR and calms immune cells, is often added to the standard anti-rejection drugs, mainly to spare the kidneys. Landoas and colleagues looked back at the records of patients treated in Grenoble and asked whether the timing and continuity of everolimus mattered. Starting it later and stopping and restarting it more often were both linked to a higher risk of CLAD. Because this was a retrospective, single-hospital study, it shows an association and not proof that early, steady everolimus prevents CLAD.
The paper follows an earlier study from the same Grenoble team, with Landoas as first author (2024), which compared 59 lung transplant patients who received everolimus on top of standard treatment with 37 who did not. CLAD was less frequent and came later in the everolimus group. PubMed lists Landoas at the Pharmacy Department of Grenoble Alpes University Hospital on five papers since 2021, including a French nursing-journal article on insulin with the hospital pharmacy team, and with Pierrick Bedouch, a professor of clinical pharmacy, as senior author on the transplant work.
No official profile was available, so training and current position beyond the PubMed affiliation are not given.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | H | Does the duration of exposure to everolimus influence the occurrence of chronic lung allograft dysfunction? LANDOAS2026 First author: in a retrospective single-centre study of lung transplant patients, later start and more interruptions of everolimus were linked to a higher risk of chronic lung allograft dysfunction. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Agathe Landoas.
ShowHide
- Pierrick Bedouch Clinical pharmacist who studies the prevention of adverse drug events and pharmacoepidemiology
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.